Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q1 2022 Results Conference Call July 28, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - President and CEO Andy Plump - President, R&D Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Conference Call Participants Hidemaru Yamaguchi - Citi Motoya Koutani - Nomura Securities Seiji Wakao - J.P. Morgan Securities Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Securities Akinori Ueda - Goldman Sachs Ayako Iwamuro Good evening everybody or good morning everybody.

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript

Japan's Takeda Pharmaceutical Co said on Thursday first-quarter profit slumped 39% percent from a year earlier, when earnings had been boosted by the sale of its diabetes drug portfolio.

Takeda sees quarterly profit drop 39% after last year's one-time gains

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance. The gain on the sale of Takeda's Japan diabetes portfolio in the first quarter of the previous fiscal year has impacted reported financial results on a year-over-year basis, as expected. The sale contributed a one-off 133 billion yen to revenue and 131.4 billion yen t

Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used a

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Axsome Therapeutics

Immunocore Holdings

Immunocore, Axsome Therapeutics, and Takeda are significantly outperforming the market this year.

What's Winning in 2022? 3 Stocks That Are Doing Fine

Belite Bio Inc

HilleVax Inc

PepGen Inc

SPDR S&P Biotech ETF

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk to a 10-year low, according to a report from Evaluate.

Biotech Public Offerings at 10-Year Low

Icahn Enterprises

These two dividend stocks have been crushing the bear market this year.

2 Best High-Yield Dividend Stocks to Buy Right Now

British American Tobacco

Donegal Group

It's not easy to be upbeat in a bear market.

3 Red-Hot Dividends In A Down Market

Fate Therapeutics

IVERIC bio Inc

Karuna Therapeutics Inc

Madrigal Pharmaceuticals

Nkarta, Inc.

Seagen

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to

Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to

Arrowhead Pharmaceuticals

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, today announced that Takeda has leased the entire leading-edge research and development project totaling approximately 600,000 square feet in Kendall Square located at 585 Third Street in Cambridge, Massachusetts. The building is expected to be ready for occupancy in 2026 and will provide 16 stories of advanced and efficient lab office space incorporating

BioMed Realty Announces Landmark Lease with Takeda at 585 Kendall to Accommodate Cambridge Expansion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with laboratories of the future featuring modern design elements and upgraded

Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Japan's yen is at its weakest in decades and inflicting high costs of imported food and fuel on households and businesses, but also proving to be an unexpected tailwind for multinationals such as pharmaceutical giant Takeda.

Takeda, Nintendo among Japanese firms quietly celebrating weak yen

Gilead Sciences

Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%.

Takeda Pharmaceutical Vs. Gilead Sciences: Who Is The Dividend King?

Costco

Innovative Industrial Properties

Improving your investing process tends to have high returns.

Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. The

Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association (EHA), June 9-12 in Vienna, Austria. Takeda's latest research in oncology focuses on enhancing and improving patient care w

Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Moderna

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Japan for Moderna's COVID-19 vaccine Spikevax™ (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. Moderna will assume responsibility for all Spikevax™ activities, including import, local regulatory, development, quality assurance and com

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022 Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period CAMBRIDGE, MA. and OSAKA, JAPAN / ACCESSWIRE / May 31, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502)(NYSE:TAK) have announced the transfer of the marketing authorization for Moderna's COVID-19 vaccine SpikevaxTM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Bayer AG

Grifols, S.A.

These three healthcare stocks should hold their value for years.

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth.

Takeda Pharmaceutical: A Bright Decade Ahead

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Earnings Conference Call May 11, 2022 6:00 AM ET Company Participants Ayako Iwamuro - IR Christophe Weber - CEO Andy Plump - R&D President Constantine Saroukos - CFO Giles Platford - President of the PDT Business Unit Julie Kim - President, U.S. Business Unit & U.S. Country Head Ramona Sequeira - President, Global Portfolio Division Masato Iwasaki - Representative Director Conference Call Participants Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Seiji Wakao - JPMorgan Chase & Co Stacy Ku - Cowen and Company Fumiyoshi Sakai - Crédit Suisse Hidemaru Yamaguchi - Citigroup Ayako Iwamuro Thank you very much for your participation in Fiscal Year 2021 Earnings webinar of Takeda Pharmaceuticals. I am Ayako Iwamuro, IR of Takeda Pharmaceuticals.

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q4 2022 Results - Earnings Call Transcript

Takeda Pharmaceutical Co said on Wednesday that 12-month operating profit slid 9.5% from the previous year.

Japan's Takeda Pharma says full-year profit slid 9.5%

News for Takeda Pharmaceutical Stock (TAK)